About Human Dopamine Receptor D2 (DRD2) Stable Cell Line

Dopamine Receptor D2 (DRD2), also known as D2 Dopamine Receptor or D2R, is a Class A G protein-coupled receptor (GPCR) and one of the most extensively studied dopamine receptors in the central nervous system. DRD2 is activated by the neurotransmitter dopamine and primarily couples to Gi/o proteins, resulting in inhibition of adenylate cyclase activity, reduction of intracellular cAMP levels, modulation of ion channel activity, and regulation of multiple downstream signaling pathways. DRD2 is widely expressed in the striatum, nucleus accumbens, substantia nigra, pituitary gland, and other brain regions involved in motor control, reward processing, cognition, motivation, and neuroendocrine regulation.

DRD2 plays a central role in dopaminergic neurotransmission and is critically involved in the regulation of movement, behavior, learning, emotional responses, and hormonal signaling. Dysregulation of DRD2-mediated signaling has been strongly associated with numerous neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, addiction, depression, Tourette syndrome, and attention-deficit hyperactivity disorder (ADHD). Importantly, DRD2 is the primary therapeutic target of many antipsychotic drugs and remains one of the most clinically relevant GPCR targets in neuroscience and neuropharmacology.

eEnzyme's Human DRD2 Stable Cell Line provides a reliable and reproducible cellular platform for investigating DRD2-mediated signaling pathways and evaluating receptor-targeted therapeutics. The cell line enables quantitative assessment of agonists, antagonists, partial agonists, inverse agonists, and allosteric modulators through cAMP assays, β-arrestin recruitment assays, reporter gene assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, compound profiling, potency determination, lead optimization, and high-throughput screening applications supporting neuroscience and psychiatric drug discovery programs.

Applications of the DRD2 Stable Cell Line

• DRD2 receptor pharmacology studies
• Dopamine signaling pathway investigations
• Antipsychotic drug discovery and development
• Agonist and antagonist screening
• Parkinson's disease research
• Schizophrenia and neuropsychiatric disorder studies
• cAMP and β-arrestin signaling assays
• High-throughput screening applications

Biological Significance of DRD2

DRD2 is a key regulator of dopaminergic neurotransmission and plays essential roles in controlling motor activity, reward behavior, cognition, and endocrine function. Activation of DRD2 modulates neuronal excitability and neurotransmitter release through Gi/o-mediated signaling pathways. In the basal ganglia, DRD2 contributes to motor coordination and movement control, while in mesolimbic pathways it influences motivation, reinforcement, and addictive behaviors. Altered DRD2 expression or signaling has been linked to schizophrenia, substance use disorders, mood disorders, and neurodegenerative diseases. Because DRD2 serves as the principal target of most antipsychotic medications and remains central to dopamine-related disease mechanisms, it continues to be one of the most important GPCR targets in neuroscience research and pharmaceutical development. The DRD2 Stable Cell Line provides a valuable tool for studying dopamine receptor biology and advancing the discovery of next-generation therapeutics for neurological and psychiatric disorders.